Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML

NCT02076191 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT02076191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Lead sponsor
John Mascarenhas
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2014
Completion date
July 20, 2018
Enrollment
49 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasms